Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

For investors eyeing Biocon’s stock, this approval could be a significant catalyst. According to InvestingPro’s fair value ...

Biocon is set for major growth in the next 2-3 years, propelled by new generics and biosimilars. The Viatris acquisition ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a ...